Protagonist Therapeutics Reports 99% Revenue Increase to $56.4 Million in Latest Quarter

Protagonist Therapeutics, Inc. reported significant financial performance improvements in its latest quarterly filing, with total revenue reaching $56.4 million for the three months ended March 31, 2026, compared to $28.3 million in the same period last year, marking a 99% increase. This surge in revenue was primarily driven by a $50 million milestone payment received following the FDA approval of ICOTYDE™ (icotrokinra) for treating moderate-to-severe plaque psoriasis. The company also recognized $6.4 million from its collaboration with Takeda Pharmaceuticals, although this represented a decrease from the previous year due to the timing of milestone payments.

Operating expenses for Protagonist increased by 26% to $60 million, up from $47.6 million in the prior year. The rise was attributed to a 30% increase in research and development expenses, which totaled $46.7 million, reflecting ongoing investments in clinical trials and new product candidates. General and administrative expenses also rose by 13% to $13.3 million, driven by higher personnel costs. Despite the increase in expenses, the company reported a net income of $3.8 million, a significant turnaround from a net loss of $11.7 million in the first quarter of 2025.

In terms of operational developments, Protagonist's employee headcount increased to 131 as of March 31, 2026, up from 124 a year earlier, reflecting the company's growth and expansion efforts. The company is actively advancing its pipeline, with ICOTYDE now in Phase 3 development for additional indications, including psoriatic arthritis and ulcerative colitis. Additionally, rusfertide, another key product candidate, is under priority review by the FDA, with a target action date in the third quarter of 2026.

Protagonist's cash, cash equivalents, and marketable securities totaled approximately $620.3 million as of March 31, 2026, a decrease from $646 million at the end of 2025. The company anticipates that its existing cash resources will be sufficient to fund operations for at least the next twelve months. Looking ahead, Protagonist expects to continue generating revenue from milestone payments and royalties from its collaboration agreements, particularly with JNJ and Takeda, as it advances its product candidates through clinical development and regulatory approval processes.